• Notice of Upcoming Request for Applications (RFA)

    The ASH Research Collaborative® (ASH RC) invites prospective research sites to submit applications to join the ASH RC Sickle Cell Disease (SCD) Research Network beginning February 10, 2025.

    Learn More
    Request for Applications

  • ASH Research Collaborative and Reagan-Udall Foundation for the FDA Launch Sickle Cell Disease Real-World Data Project

    The Real-World Evidence Consortium for Sickle Cell Disease will develop consensus on how to use data collected from electronic health records for research and to improve care.

    Read Article
    Slideshow Real World Evidence Consortium

  • Real-World Evidence Initiative Reports Now Available

    The Real-World Evidence Initiative is excited to share the final recommendations from the Genomic Therapies and the Coordinated Registry Network Work Groups. The reports chart out a future path for regulatory science and for genomic therapies.

    Final Recommendations
    Slider Image 1

  • The ASH Research Collaborative: Real-World Data Infrastructure to Support Real-World Evidence Development and Learning Healthcare Systems in Hematology

    ASH RC, in collaboration with the FDA, published an article focused on leveraging real-world evidence to support healthcare.

    Read Article
    Slider Image 4

  • Data Hub Video Series: Overview, Data Capture, Data Quality, Access and Use and Future Developments

    Dr. Bill Wood, Chair for the Data Hub Oversight Group, provides an overview of the Data Hub in this two-part video series.

    Overview & Data Capture Data Quality, Access, & Use
    Slider Image 7

  • Connect With Us on Social Media

    Follow us on Twitter/X and Facebook as we share the latest updates from ASH RC and connect with those who are also working to improve the lives of people affected by blood diseases.

    Facebook Twitter/X
    Slider Image 8
123456

Improving Research to Build a Brighter Future for People with Hematologic Conditions

Individuals living with hematologic conditions need more evidence-based options for managing their health and improving their quality of life. The ASH Research Collaborative® (ASH RC) is working to accelerate change by making it more efficient to conduct research, from increasing access to high-quality clinical data to making it easier for individuals with hematologic conditions to participate in studies.

The ASH RC is currently focused in two disease areas: One classical hematologic condition, sickle cell disease (SCD), and one malignant hematologic disease, multiple myeloma (MM).

  • At the heart of both programs are site-based Research Networks consisting of experts in their respective fields.
  • The SCD Research Network fosters collaborative partnerships to accelerate progress in clinical research and improve outcomes for individuals living with SCD by expediting the development of therapeutics and generating high-quality evidence to support clinical decision-making. Learn about the SCD Research Network.
  • The MM Research Network is committed to building relationships within the myeloma community, leveraging the power of real-world evidence, and prioritizing research to improve the lives of individuals living with multiple myeloma. Learn about the MM Research Network.

Both Networks are powered by real-world data (RWD) which we call The Data Hub. The Data Hub is designed to be the largest shared information resource with real-world data to serve the hematology community. Access to these data can accelerate research and development, support regulatory decision-making, and help clinics identify opportunities for quality improvement. Learn about the Data Hub

ASH RC Home

Latest Announcements

News & Events

Multiple Myeloma Research

ASH RC Data Hub’s Multiple Myeloma Program Accelerates Research

The ASH Research Collaborative (ASH RC) Data Hub’s Multiple Myeloma Program can feasibly collect patient data from its participating sites for prospective evidence generation, according to new research presented at the 66th ASH Annual Meeting and Exposition.
Read more
Covid-19, Multiple Myeloma

Innovative ASH RC Study Quickly, Effectively Generates COVID-19 Data in Patients with Multiple Myeloma

An innovative study of patients with multiple myeloma rapidly accrued a diverse cohort, demonstrated high consent/adherence rates, and assessed COVID-19 outcomes and their impact on quality of life. The research was presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, and online.
Read more
Sickle Cell Disease Diagnosis Type

ASH RC Data Hub Accurately Confirms SCD Diagnosis Type

The ASH Research Collaborative (ASH RC) Data Hub, which was developed to facilitate research and quality improvement through real-world data, accurately correlates sickle cell disease (SCD) genotype with verified diagnoses, validating existing and future clinical data in the ASH RC’s Data Hub, according to new research presented today at the 66th ASH Annual Meeting and Exposition.
Read more
Disease Modifying Therapies (DMTs)

Disease-Modifying Therapies Remain Underused in SCD Despite Safety and Efficacy

ASH Research Collaborative study finds that only one-quarter of patients living with SCD are prescribed a DMT
Read more
ASH RC

ASH Research Collaborative to Present Data at 66th ASH Annual Meeting and Exposition

Presentations highlight how real-world data accelerate research and improve hematology care.
Read more
Multiple Myeloma Research

Notice of Upcoming Request for Applications (RFA)

The ASH Research Collaborative (ASH RC) Data Hub’s Multiple Myeloma Program can feasibly collect patient data from its participating sites for prospective evidence generation, according to new research presented at the 66th ASH Annual Meeting and Exposition.
Read more
ASH RC

Inaugural Members Appointed to ASH RC Board of Directors

The ASH Research Collaborative® (ASH RC) is proud to announce its Board of Directors, a diverse group of hematologists and data, health systems, and informatics experts committed to advancing critical research and accelerating positive change for people living with hematologic conditions.
Read more
ASHRC & Regan-Udall Foundation for FDA

ASH Research Collaborative and Reagan-Udall Foundation for the FDA Launch Sickle Cell Disease Real-World Data Project

The ASH Research Collaborative (ASH RC) and the Reagan-Udall Foundation for the Food and Drug Administration (FDA Foundation) are launching the Real-World Evidence Consortium for Sickle Cell Disease (SCD) to develop consensus recommendations on clinical outcomes important to treating people with SCD and apply those standards to real-world data sets.
Read more
12345678

Follow Us On Twitter/X

@ASHCOLLAB